Posts tagged trial design
Canopy Health aims to evolve medical cannabis as a natural drug product and disrupt pharma market

As president and CEO of newly formed Canopy Health Innovations, a spin off of Canopy Group (TSX:WEED), a world leading diversified cannabis company, Marc Wayne is a pioneer of the medical cannabis sector. He was a co-founder of Bedrocan Canada, one of Canada’s first licensed producers of medical cannabis, and founding chairman of the Cannabis Canada Association, a trade group with 17 licensed producers...

Read More
Histogenics to complete Phase 3 enrollment in Q2

Histogenics (NASDAQ:HSGX) expects to complete enrollment by the end of the second quarter this year in a Phase 3 clinical trial of its NeoCart biologic cell therapy and tissue engineering solution for knee cartilage regeneration.

Read More
In conversation with David Luci

As president, CEO and a co-founder of Dipexium Pharmaceuticals (NASDAQ:DPRX), David Luci, and executive chairman and co-founder, Robert DeLuccia, have spearheaded development of Locilex, which could be the first FDA-approved antibiotic specifically to treat mild infections of diabetic foot ulcers (DFI). The two men were instrumental in acquiring the worldwide writes to Locilex five years ago and leading its reformulation and clinical progress. They are experienced pharmaceutical executives with a proven track record of success in drug development and partnering with, and selling to, Big Pharma. In this interview with, Mr. Luci discusses the clinical status of Locilex in the U.S., plans for regulatory approval in Europe and commercialization.

Read More